CD274 and non-small cell lung carcinoma: Another study is evaluating the combination of pembrolizumab with binimetinib in patients with metastatic or advanced NSCLC with PD-L1 > 50%, and initial results reported 36% of patients with partial response (NCT03991819) [95].